Koch, C. J. | Search bioRxiv

bioRxiv2026

Decreased Damage for proton FLASH vs Conventional Dose Rates in Mouse Jejunum Shown by Quantitative Assessment of γ-H2AX

Purpose: FLASH radiation with ultra-high dose rate delivery is less damaging to normal tissue than conventional radiation ( <1 Gy/s). Since radiation depletes oxygen (ROD), this damage reduction might occur via the oxygen effect. ROD experiments have shown an oxygen-independent reduction in dose effectiveness at FLASH dose rates. However, prior in vivo ROD measurements relied on extracellular oxygen probes that could not penetrate cell membranes, leaving intracellular effects unresolved. To investigate the ROD hypothesis more directly, we developed a novel three-component immunohistochemical assay with algorithmic image processing to quantitatively compare DNA damage following FLASH and conventional irradiation in mouse jejunum. Methods: Mice received intravenous EF5 2 hours before proton irradiation at FLASH (103.63 +/- 17.2 Gy/s) or conventional (0.73 +/- 0.1 Gy/s) dose rates of 2.5 Gy or 5 Gy, with unirradiated controls. Mice were euthanized 30 minutes post-irradiation, and 10 cm of jejunum was frozen as a 'Swiss Roll', sectioned, stained, and imaged. Tissue sections were stained for {gamma}-H2AX, DRAQ5, and EF5 to assess DNA double-strand breaks, total DNA content, and hypoxia, respectively. An in-house algorithm identified individual cell nuclei and registered each nucleus with its corresponding {gamma}-H2AX and EF5 signals, enabling quantitative measurement of DNA damage as a function of local tissue hypoxia. Results: Hypoxia was greatest in the villi and, to a lesser extent, the outer jejunal musculature, with substantial inter-animal variation. DNA damage decreased in hypoxic regions. FLASH enhanced the hypoxia-associated reduction in DNA damage compared with conventional dose rate and, separately, revealed an oxygen-independent reduction in DNA damage, suggesting an additional FLASH sparing mechanism. Conclusion: Current results suggest that FLASH compared to conventional dose rate radiation caused less DNA damage with increasing effect at low oxygen levels, a result consistent with ROD as a mechanism. Pronounced tissue heterogeneity in murine jejunum requires further studies to segment the effect for each tissue type.

biophysics↗

bioRxiv2026

Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8+ T cell recognition via mitochondrial neoantigen presentation

Renal cell carcinoma (RCC) frequently exhibits resistance to immune checkpoint blockade, highlighting the need for strategies that enhance tumor-specific T cell priming and improve immune access to the tumor microenvironment. Here we show that vaccination targeting tumor-associated mitochondrial antigens (TAMAs), derived from tumor-specific mitochondrial DNA (mtDNA) missense mutations, synergizes with PD-1/PD-L1 blockade to overcome checkpoint refractoriness in the RENCA RCC model. TAMAs vaccination elicits antigen-specific T cell responses, increases intratumoral CD8+ T cell infiltration, and reduces immunosuppressive myeloid populations, resulting in delayed tumor progression and improved survival when combined with checkpoint inhibition. In parallel, TAMAs + checkpoint blockade induces vascular remodeling characterized by increased pericyte coverage, reduced vascular leakage, improved perfusion and reduced hypoxia. Mechanistically, vascular remodeling is driven by CD8+ T cell-dependent, IFN{gamma}-associated immune activity and is associated with endothelial apoptosis and diminished intratumoral CD31 signal. We further identify tumor-to-endothelium mitochondrial transfer as a mechanism linking mitochondrial neoantigens to the tumor vascular compartment: tumor-derived mitochondria enter human and mouse endothelial cells in vitro and in vivo, and tumor-associated mtDNA mutations are detectable in endothelial fractions from murine tumors and human RCC specimens. Human endothelial cells can present mitochondrial neoantigens via MHC class I and become targets of TAMAs-specific CD8+ T cell cytotoxicity, including following mitochondrial acquisition from tumor cells. Together, these findings establish mitochondrial neoantigen immunity as a tractable approach to enhance checkpoint responses and reveal mitochondrial transfer as an antigenic bridge that expands immune targeting to the tumor vasculature.

cancer biology↗